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The acquisition of iron is essential for the survival of
pathogenic bacteria, which have consequently evolved a
wide variety of uptake systems to extract iron and heme
from host proteins such as hemoglobin. Hemoglobin pro-
tease (Hbp) was discovered as a factor involved in the
symbiosis of pathogenic Escherichia coli and Bacte-
roides fragilis, which cause intra-abdominal abscesses.
Released from E. coli, this serine protease autotrans-
porter degrades hemoglobin and delivers heme to both
bacterial species. The crystal structure of the complete
passenger domain of Hbp (110 kDa) is presented, which
is the first structure from this class of serine proteases
and the largest parallel -helical structure yet solved.
Autotransporters (ATs)1 are virulence proteins produced by
a variety of pathogenic bacteria, including several types of
Escherichia coli associated with severe, even fatal, diarrhea
and urinary tract infections. An increasing number of these
proteins have been discovered over the last decade, and a large
body of research is now devoted to these proteins and their
different roles in various diseases. ATs have evolved a unique
export mechanism, the type V pathway (1, 2). Initially the
protein is synthesized with an N-terminal leader peptide di-
recting the protein to the periplasm via the signal recognition
particle (SRP) (3). Once across the inner membrane, the C-
terminal domain forms a -barrel structure within the outer
membrane, allowing the passenger domain to escape to the
external medium, where it is released proteolytically from the
cell (4–6). Recently the crystal structure of a translocator
(membrane) domain of an AT has been solved (7). AT passenger
domains are generally more than 100 kDa in size and vary
widely in sequence and function but include a group of closely
related serine proteases, the SPATE family (serine protease
autotransporters of the Enterobacteriaceae). These proteins
are found only in pathogenic bacteria, but their precise roles
remain unknown (8, 9). The SPATE family includes EspC from
enteropathogenic E. coli (10), EspP from enterohemorrhagic
E. coli (11), plasmid-encoded toxin (Pet) from enteroaggrega-
tive E. coli (12), Sat from uropathogenic E. coli (13), Tsh and
Vat from avian pathogenic E. coli (14, 15), and Pic and SepA
from Shigella flexneri (16, 17). These AT proteins are associ-
ated with a number of serious, possibly life-threatening dis-
eases affecting millions world-wide. Tsh and Vat are essential
virulence factors in avian diseases that cost the poultry indus-
try millions of dollars annually. SPATE proteins do not appear
to have conserved or even related functions (8, 9). Vat has
vacuolating activity, and Pet enters eukaryotic cells to disturb
the cytoskeletal system. As essential proteins in pathogenesis,
SPATE proteins are key drug targets and potential routes to
vaccines. Knowledge of the molecular structure is a first step
toward understanding their mechanisms and hopefully how
they may be inactivated. We have solved the crystal structure
of the passenger domain of heme binding hemoglobin protease
(Hbp), an AT involved in bacterial synergy in the development
of peritonitis.
Peritonitis is an inflammation of the peritoneal cavity and
may develop into a life-threatening condition through the for-
mation of persistent abscesses, which leak pathogenic bacteria
into the general circulation (18, 19). This common complication
of invasive surgery then results in septic shock and multiorgan
failure with mortality rates well in excess of 50%. These ab-
scesses are difficult to treat with antimicrobial therapy, and
usually require surgical intervention. It is frequently found
that pathogenic E. coli and the strictly anaerobic Bacteroides
fragilis occur together in intra-abdominal abscesses, the com-
bination surviving better than either species alone (20, 21).
B. fragilis is a common member of the normal human gut flora,
but it is also a significant opportunistic pathogen (18, 19). It
promotes fibrin deposition by the host, which localizes the
bacteria and prevents systemic spread, but also provides an
environment where the bacteria can escape attack by the im-
mune system. In return, E. coli helps to supply both species
with heme scavenged from hemoglobin (Hb). Hbp was discov-
ered as the protease secreted by E. coli, which degrades Hb and
binds heme (21, 22). The hbp gene is located on a large episome,
pColV-K30, which also encodes an aerobactin-dependent iron
uptake system (23). Hbp is highly expressed by E. coli during
peritonitis and plays a key role in bacterial synergy with
B. fragilis. Adding Hbp and heme to cultures of B. fragilis was
shown to stimulate growth, and mice immunized with Hbp
showed no abscess formation when subsequently challenged
with mixed E. coli/B. fragilis cultures. Hbp therefore appears to
be a useful target in the treatment and prevention of peritoni-
tis. We have determined the crystal structure of Hbp with the
longer term view of producing inhibitors, vaccines, or other
treatments for peritonitis and other diseases caused by SPATE
proteins. From this first molecular model of an AT, we have
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constructed homology models of other ATs to observe both
common and unique features of these proteins.
MATERIALS AND METHODS
Protein Purification and Crystallization—The cloning of Hbp has been
described previously (22). E. coli strain DH5 harboring plasmid pACY-
CHbp was grown to an A600 of 0.6 in MA medium, and the supernatant
was collected and concentrated. Following 1000-fold concentration by
ultrafiltration, the protein was purified by gel filtration in 10 mM Tris-Cl,
pH 8.0, 300 mM sodium chloride. Apo-Hbp was crystallized by the pub-
lished method (24). 4 mg/ml protein was crystallized using the hanging
drop method using 0.1 M sodium acetate, pH 4.6, 200 mM ammonium
sulfate, 10% glycerol, and 15–20% polyethylene glycol 6000.
Data Collection and Processing—Multi-wavelength x-ray data were
collected at beam line 45XU-PX, SPring8, Harima, Japan. Native data
were collected at beam line BL5 of the Photon Factory, Tsukuba, to a
resolution of 2.2 Å. All data were indexed and integrated using
HKL2000 and scaled with the program SCALEPACK (25). The crystals
are in space group P6122 with unit cell dimensions of a  b  114.86 Å,
c  437.05 Å, with one molecule per asymmetric unit and a solvent
content of 65%.
Structure Determination and Refinement—The structure of Hbp was
solved by MAD (multiple-wavelength anomalous dispersion) using sel-
enomethionine-containing protein. Phase determination and refine-
ment were performed using the programs SOLVE and RESOLVE (26,
27). 12 Se sites were located out of 14 expected. The 3.0-Å resolution
electron density map obtained from RESOLVE was of sufficient quality
to permit unambiguous chain tracing without further refinement of the
heavy atom sites. After model building using the programs O (28) and
Turbo (29), initial refinement was carried out with XPLOR (30) and
final refinement with REFMAC (31, 32) using the 2.2-Å resolution
native data. Solvent molecules were placed at positions where spherical
electron-density peaks were found above 1.5  in the 2Fo  Fc map and
above 3.0  in the Fo  Fc map and where stereochemically reasonable
hydrogen bonds were allowed. The final model extends from the N
terminus (residue 1 of the mature protein) to residue 1048, the C-
terminal residue of the passenger domain. The Ramachandran plot has
86% of the residues in the most favorable regions and none in disal-
lowed regions. A summary of the data collection and refinement statis-
tics is given in Table I. The final model and structure factors have been
deposited in the Protein Data Bank (PDB, 1WXR).
RESULTS
The overall structure of the protein is shown in Fig. 1. The
most striking feature is the right-handed -helical C-terminal
tail, which extends from residue 260 onwards, forming three
parallel  sheets. This is highly similar to pertactin (PDB
1DAB) (33) and the N terminus of filamentous hemagglutinin
(PDB 1RWR) (34), both adhesins from Bordetella pertussis.
Pertactin is the only AT structure refined to date, one of only a
dozen or so right-handed parallel  helix protein structures so
far solved. The first was the pectate lyase PelC (PDB 1AIR),
FIG. 1.A stereo ribbon diagram showing the overall structure of
the entire passenger region of Hbp. Helices and strands are colored
red for the protease domain (domain 1, residues 1–256) and green for the
chitinase b-like domain (domain 2, residues 481–556). The  strands in
the parallel  helix are colored dark blue. Residues 950–1048 (the C
terminus of the mature protein) are colored light blue. This region is
required for transport of the passenger domain through the membrane
pore created by the C-terminal region of the complete protein.
TABLE I
Data collection and refinement statistics
Space group, unit cell dimensions (Å) P6122, a  b  114.86, c  437.05
Wavelength (Å) Peak Inflection Remote
Resolution range (Å) 50.0–3.0 50.0–3.0 50.0–3.0
Reflections (measured/unique) 214,532/33,539 242,451/34,130 232,344/33,910
Completeness (overall/outer shell, %)a 95.4/88.5 98.8/92.6 96.0/87.7
Rmerge (overall/outer shell, %)
a,b 10.2/21.2 8.3/18.3 8.5/18.8
Redundancy (overall) 6.4 7.1 6.9
Mean I/(I) (overall) 7.8 8.9 8.3
Phasing (20.0–3.0 Å)
Mean FOMc after SOLVE phasing 0.33
Refinement statistics
Refinement resolution (Å) 30.0–2.20
Reflections (measured/unique) 525,426/81,279
Completeness (overall/outer shell, %)a 92.3/70.8
Rmerge (overall/outer shell, %)
a,b 5.8/31.8
Redundancy (overall) 6.5
Mean I/(I) (overall) 11.0
 cut-off /reflections used 0.0/81,279
R-factord/free R-factor (%)b 20.3/24.3
Root mean square deviation bond lengths/bond angles (Å) 0.016/1.7
Water molecules 399
Average B-factor (protein/water, Å2) 35/33
Ramachandran plot
Residues in most favorable regions (%) 86.1
Residues in additionally allowed regions (%) 12.9
Residues in generously allowed regions (%) 1.0
aCompleteness and Rmerge, are given for overall data and for the highest resolution shell (overall/the highest resolution shell). The highest
resolution shells for the MAD data and native data are 3.11–3.0 Å and 2.28–2.20 Å, respectively.
b Rmerge   Ii  I/ Ii ; where Ii is intensity of observation and I is the mean value for that reflection.
c Figure of merit (FOM)  Fbest/F .
d R factor  Fo(h)  Fc(h)/hFo(h); where Fo and Fc are the observed and calculated structure factor amplitudes, respectively. The free
R-factor was calculated with 5% of the data excluded from the refinement.
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and a number of different pectate lyase structures are now
known (35). The pectate lyase superfamily members are a
functionally eclectic mix, including P22 tailspike protein (PDB
1TYU), chondroitinase B (PDB 1DGB), and insect cysteine-rich
antifreeze protein (PDB 1EZG). All share a similar pattern of
repeats of about 25 amino acid residues, which form one turn of
the right-handed helix. Each turn creates three  strands that
form extended  sheets with neighboring turns. The core of this
region is generally but not exclusively hydrophobic. The
leucine-rich repeat family is another group of protein struc-
tures formed from repeated sequence motifs, but these include
an  helix in each turn and are found to be highly curved into
horseshoe shapes. The pectate lyase superfamily forms a much
straighter superhelix. The shape of Hbp was previously deter-
mined to low resolution using a combination of small-angle
x-ray scattering and analytical ultracentrifugation (36). The
crystal structure shows a slightly straighter structure than the
model from small-angle x-ray scattering, possibly due to
greater flexibility in solution.
The Hbp model includes 24 turns of right-handed  helix,
compared with 16 in pertactin, the longest parallel -helix
known to date. Hbp is highly reminiscent of pertactin, but less
regular and slightly kinked in the center. It also has a large
N-terminal globular domain and a smaller domain of 75 resi-
dues (481–556) about half-way along the -helix, as well as
decorative loops where the polypeptide chain departs from the
helical stem. The extra surface features make the length of Hbp
(1048 residues) almost twice that of pertactin (539 residues).
The extended hydrophobic core is largely but not exclusively
filled with aliphatic side chains (Fig. 2, top and bottom). The
N-terminal region close to the serine protease domain has a
higher proportion of buried aromatic residues. Very few polar
residues point into the hydrophobic core, but Ser780 is one
exception (Fig. 2, bottom). Other SPATE proteins generally
have threonine at this position. Unlike the pectate lyases there
are no regular “stacks” of identical residues packed in layers
within the core, but a row of asparagine residues is found
forming an extended hydrogen bonding chain on the surface of
the  helix (Fig. 3). Overall the electron density for the model is
very clear, but model building became increasingly difficult
toward the C terminus. LAFIRE, a model fitting and rebuilding
FIG. 2. Top, a slice through the  helix
showing the hydrophobic core. The back-
bone is shown as a green ribbon, and hy-
drophobic side chains are shown in pink.
Bottom, the 2mFo  DFc electron density
map, shown in stereo and contoured at
1.3, showing a cross-section through the
 helix.
FIG. 3. An orthogonal view to Fig. 2 (bottom) of the final 2mFo 
DFc electron density map, at the same contour level, showing a
stack of asparagine residues on the surface of the  helix (colored
red), which are hydrogen bonding through their side chains. These
asparagines are not conserved amongAT sequences, which have a variety of
hydrophilic side chains at equivalent positions.
Structure of Heme Binding Protein 17341
 at Vrije Universiteit, Medical Library, on December 21, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
program using local correlation of electron density,2 was essen-
tial in assembling the last 100 residues of the model. Details of
the program may be found at: altair.sci.hokudai.ac.jp/g6/
Research/Lafire_English.html. There are several breaks in the
final electron density maps in this region where short loops
cannot be modeled. The C-terminal region from residue 950 to
the end is a conserved domain found among AT proteins be-
lieved to assist folding after passage through the C-terminal
pore domain (37).
Residues 1–256 of the model form a clearly separate domain
(domain 1 in Fig. 1), including six  strands rolled into a
barrel-like structure, with several long  hairpins over its
surface. The N-terminal glycine residue is deep within the
structure, close to the bottom of the barrel. Folding of the
domain can clearly only occur after the signal peptide has been
removed. The glycine N atom hydrogen bonds to Asp206, which
also interacts with Arg140 and the main-chain of Gly144. An
-helix (Leu245-Asp255) connects this domain to the  helical
stem. Searching the PDB for structural homologues with DALI
(38, 39) revealed that the N-terminal domain is highly similar
to bovine trypsin (PDB 5PTP), which gave a Z-score of 17.5
(scores above 2.0 are considered significant). The 162 residues
matched showed 20% sequence identity to Hbp and could be
fitted with root mean square deviation of 2.5 Å over the main
chain. The C traces are overlaid in Fig. 4, top. Other proteases
gave rather poorer scores. Overlaying trypsin on the model of
Hbp gave an excellent match of the catalytic triad (Ser195,
His57, and Asp102) of trypsin with Ser207, His73, and Asp101 of
Hbp (Fig. 4, bottom). Comparing the active sites, Hbp misses a
loop (Ser93 to Asp101 in trypsin) just prior to the essential
aspartate. In trypsin this loop includes Leu99, which contacts
Trp215, one of the residues that forms antiparallel- sheet
interactions with the substrate polypeptide. Trp215 in trypsin is
changed to alanine (Ala229) in Hbp, making the active site of
Hbp much more open. At the bottom of the specificity pocket,
which accommodates the residue preceding the scissile bond,
trypsin has an aspartate (Asp189), which leads to the preference
for Lys and Arg residues at the S1 position. Chymotrypsin and
elastase have serine in this position, but Hbp has tyrosine
(Tyr201). Among the trypsin/chymotrypsin family, Pro225 is
very highly conserved from bacteria to man, but Hbp misses a
loop just before this residue, and the nearest equivalent is
Gly237. Hbp is also unusual in having an asparagine residue at
the position equivalent to glycine 226 in trypsin. Thus, al-
though the fold of the N-terminal domain is close to trypsin, it
also has unique features not seen in other serine proteases. The
active site suggests broad substrate specificity with a prefer-
ence for hydrophobic side chains in the specificity pocket. The
very open active site presumably helps Hbp to attack folded
globular proteins such as Hb, but more work is required to
determine its functional properties as a protease. Low resolu-
tion electron density maps calculated using data collected with
crystals soaked with two serine protease inhibitors, tosylphe-
nylalanine chloromethyl ketone and tosyllysine chloromethyl
ketone, show peaks of density close to the active site serine,
suggesting the protease is still active at pH 4.6 (data not
shown).
Sequence alignments of SPATE family members shows the
sequence GDSGSPL to be highly conserved between Gly205 and
Leu211 (Fig. 5). vat, an AT gene found in a pathogenicity island
of avian pathogenic E. coli Ec222, has a slightly altered se-
quence, ATSGSPL, which may be related to its vacuolating
activity (15), but it maintains both the active site serine
(Ser207) and Ser209, which hydrogen bonds to the carbonyl
oxygen of Asp206 to make the turn carrying Ser207. The N-
terminal Gly1 lies close to the active site serine and hydrogen
bonds to the side chain of Asp206. This strongly suggests the
enzyme can only become active after the leader peptide is
removed. All SPATE proteins tested show proteolytic activity,
but with different substrate specificities, suggesting different2 M. Yao, unpublished program.
FIG. 4. Top, a stereo overlay of the C
trace of bovine trypsin (blue) and the ser-
ine protease domain of Hbp (red). The C
of the catalytic serine (Ser207) is shown as
a green sphere. Trypsin (PDB 5PTP) was
matched to HBP by least-squares fitting
residues 16–19 (1–4), 21–24 (15–18),
26–32 (49–55), 42–60 (58–76), 63–69
(78–84), 79–93 (85–99), 101–114 (100–
113), 118–127 (114–123), 129–132 (128–
131), 134–146 (136–148), 147–152 (156–
161), 153–165 (163–175), 176–183 (177–
184), 184–187 (186–189), 188–202 (200–
214), 224–231 (236–243), and 234–245
(244–255). These 648 main-chain atoms
selected by DALI have a root mean square
deviation of 2.5 Å, and a maximum devi-
ation of 8.2 Å. Bottom, the 2mFo  DFc
electron density map contoured at 1.3
over the catalytic site of the serine prote-
ase domain, showing the catalytic serine
(Ser207) and a water molecule hydrogen
bonded to it. Tyr201, the residue in the
specificity pocket, is seen on the lower left.
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functions (9). Replacement of the active site serine of Pet (a
SPATE from enteroaggregative E. coli) with isoleucine did not
prevent release of the passenger domain from the C-terminal
pore, but did eliminate all cytotoxic effects (40). Comparing the
sequences of various ATs shows that Tyr201 in the specificity
pocket of Hbp is preserved in Pic and SepA, whereas Pet and
Sat have leucine (Fig. 5). The sequence alignment also suggests
that EspC has glutamate at this position, which presumably
would affect substrate preference strongly. Using the N domain
structure of Hbp, a homology model of Pet protease domain was
built using SwissModel (41). From this a second homology
model of Sat protease domain was also constructed. The
weaker sequence conservation between Hbp and Sat prevented
a model of the latter being built more directly. These homology
models show no unexpectedly loose packing or unfavorable
geometry, indicating that each protein has identical connectiv-
ity, with minor differences in loop regions, in the N-terminal
protease domain.
The N-terminal domain makes extensive contact with the
-helical stem of Hbp, but given its globular shape the contact
region with the roughly cylindrical  helix is long and narrow.
Many N domain contacts are found between Asp108 and Val114.
Arg106 makes buried hydrogen bonds to the carbonyl oxygen
atoms of Asn301 and Gly303. The main hydrophobic contact is
provided by Leu110, which is buried at the interface. Arg106 and
Lys109 are very strongly conserved among ATs, the latter forming
a salt bridge with Asp367. Arg441 and Asp49, both well conserved,
make another bond between theN-terminal protease domain and
the -helix. These contacts, and the preservation of key glycines
in the sequences of ATs, suggest that these proteins share a very
similar structure over the first half of the protein.
Residues 481–556 of Hbp make a small separate domain
(domain 2 in Fig. 1), the main chain returning to the  stem
close to the point of departure. DALI found only one notable
match, to the chitin binding domain of chitinase b (PDB 1E15).
This domain consists of only 49 residues folded into three
antiparallel  strands connected by long loops. The chitin bind-
ing domain fitted the 481–556 loop of Hbp with a Z-score of 3.6
FIG. 6. Heme binding by Hbp. PCR was used to create an Hbp
mutant (called “Gdel-2”) missing domain 2 by linking Ala481 to Asn556
with a glycine residue. Purified native Hbp and Hbp(Gdel-2) (20 pmol)
were incubated with different concentrations of heme and subsequently
subjected to nondenaturing gel electrophoresis as described previously
(22). Heme containing proteins were visualized by tetramethyl benzi-
dine staining. The upper panel shows the tetramethyl benzidine-
stained gel; lanes 1–3, Hbp incubated with 0, 50, or 100 pmol of heme,
respectively. Heme binding, shown by the dark band, is unchanged in
the mutant. Lanes 4–6, Hbp(Gdel-2) incubated with the different
amounts of heme. The lower panel shows the Coomassie Blue-stained
gel of Hbp and Hbp(Gdel-2). The lower molecular weight of the mutant
is apparent.
FIG. 5. A sequence alignment of Hbp with other members of the SPATE family, covering the N-terminal protease domain.
Conservative mutations are shown in red, and residues common to all of the six compared sequences are shown in white on red. The UNIPROT
reference numbers for the sequences are O88093 (Hbp), Q8CWC7 (Pic), Q8VSL2 (SepA), P77070 (EspC), Q6KD43 (Sat), and O68900 (Pet).
Secondary structure elements of Hbp are shown over the alignment. The conserved regions show strong correlation to these structural elements,
with the exception of the catalytic region GDSGS. The side-chain four residues upstream from this sequence sits in the specificity pocket (Tyr201
in the case of Hbp).
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over 44 residues, with 16% sequence identity. Not surprisingly,
the surface aromatic groups of chitin binding domain presumed
to bind chitin are altered in Hbp, but the 481–556 loop has a
different cluster of aromatic residues, which appear to form a
binding pocket of some sort. Tyr510 and Tyr526 point into sol-
vent and are highly exposed (and make crystal contacts with a
neighboring molecule). The nearby Trp492, Tyr506, and Phe527
make a hydrophobic pocket open to solvent. The 481–556 do-
main is quite different to any known heme-binding site, and a
mutant in which this domain is deleted shows identical heme
binding to the wild-type protein (Fig. 6). Possibly its function is
docking to extracellular matrix proteins or the bacterial recep-
tor proteins, but these have yet to be identified. Using residues
250–615 from the Hbp model, a homology model of the same
region could be built (again using SwissModel) for Pic. Key
residues such as Glu538 and Arg554, which hold domain 2
against the -helix by a salt bridge, are preserved in Pic.
Sequence alignment of ATs shows that Pet, Sat, and EspC
among others do not have this domain.
Residues 608–644 of Hbp form a long discursive loop pro-
jecting from the -helix, which also forms close contacts with
the N domain. Thr616-Ala626 forms an  helix, but this probably
requires hydrophobic contact with the N domain residues Tyr9
and Met158 to form. The 608–644 loop has no hydrophobic core
of its own to suggest it is a stable independent fold. Because
other ATs show no homology to Hbp in this region, it may be
the heme binding site. Residue 629 is histidine, which is the
most common residue bonding to heme groups, but the struc-
ture does not readily suggest how heme might bind. Repeated
attempts to co-crystallize Hbp with heme or soak the crystals
were unsuccessful, and mutagenesis is now underway to test
the function of this region. The charge distribution over the
molecular surface shows a concentration of negative charge on
one face of the molecule, centered around the interface between
the  helix and domain 1 (Fig. 7). Further mutagenesis is
required to determine whether this negatively charged patch is
involved in heme transport.
Sequence similarity among ATs shows an increase again
toward the C-terminal region of the passenger proteins. Gly-
cines 868 and 875 in turns of Hbp are completely preserved, as
are Met886 and Trp891. The -helix structure is broken at the
conserved Ala979/Pro980, which mark a change in the direction
of the polypeptide chain. Breaks in the electron density pre-
vented modeling residues 913–918, 937–941, and 1024–1031.
Despite the sequence conservation over the last 140 residues,
these gaps in the Hbp model prevented making homology mod-
els of this region. The pattern of preserved residues matches
very well interactions seen in the Hbp structure, however, and
the C-terminal region of other ATs presumably shows a very
similar fold. Key residues include Trp1015, which is buried and
forms a hydrogen bond through its indole side chain to make a
turn in the protein backbone.
Hbp has been shown to cross the inner membrane by the
signal recognition particle (SRP)-dependent pathway (3), but
the precise mechanism of transport across the outer membrane
of the cell remains unclear. Several different proposals have
been made, including the suggestion that autotransporters
form a multimeric pore in the outer membrane (42). Recently
the structure of the pore-forming domain of NalP has been
solved, showing that it is in fact a monomer, a 12-stranded
-barrel blocked by an N-terminal  helix (7). The pore diam-
eter, roughly 10–12 Å, is insufficient to allow passage of folded
proteins and suggests that only extended polypeptides can pass
through. This appears incompatible with the idea that the
passenger domain is threaded through from its C-terminal end
(the hairpin model), because the pore would then have to ac-
commodate two stretches of polypeptide simultaneously. An
alternative model is that the N terminus of the passenger
domain is threaded through the pore, but, because other pro-
tein domains fused to the pore domain are also transported,
there is no evidence of sequence-specific interactions that tar-
get the N terminus to the pore. Oomen and colleagues (7) have
suggested that the passenger domain may instead pass though
the pore of the Omp85 complex, and that the name “autotrans-
porter” is in fact a misnomer. From the crystal structure of Hbp
described here, it is clear that the C-terminal domain (residues
950–1048) of the mature protein is more flexible and mobile
than the N-terminal protease domain. This is consistent with
the prediction that the C-terminal domain plays a key role in
passage across the outer membrane. On the other hand, be-
cause the N-terminal glycine of the mature protein is buried
within the structure, the protease domain cannot fold properly
until the signal peptide is removed, and this may provide a
mechanism for keeping the protein in a readily transported
form.
Tsh (temperature-sensitive hemagglutination), a SPATE
found in avian pathogenic E. coli, has only two amino acid
changes compared with Hbp (14, 43, 44), but Hbp showed no
hemagglutination activity in tests (22). Recently this result has
been confirmed for Tsh (45). The two mutations, Lys157 3 Gln
and Thr790 3 Ala, are both on the protein surface. Lys157 is
roughly 18 Å from the active site, but replacement with gluta-
FIG. 7. Surface charge of Hbp. The
molecular surface of the protein, colored
by electrostatic charge (red, negative;
blue, positive). Color saturation corre-
sponds to an electron energy of 20 kBT.
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mine seems unlikely to alter the functional behavior of the
protein greatly. Hbp and Tsh are therefore essentially identi-
cal, suggesting that Tsh too is a hemoglobin protease. If so,
then the name “Tsh” seems redundant, and we suggest the
name “Hbp” be used exclusively in the future. Tsh has been
shown to bind red blood cells, hemoglobin, fibronectin, and
collagen IV (45). It remains to be tested which of these are
bound by domain 2.
DISCUSSION
Hbp was first purified from E. coli EB1, a strain isolated from
an intra-abdominal wound infection (22). Without Hbp, E. coli
and B. fragilis are unable to form abscesses and are more readily
cleared from the site of infection by the immune system, presum-
ably due to iron limitation. Although a great deal is known about
iron-uptake by pathogens through siderophores, very few bacte-
rial heme uptake systems have been characterized in molecular
detail. The best understood is the HasA protein of Serratia mar-
cescens for which a crystal structure has been refined to 1.9 Å
(46). Hbp has a quite different fold, and is over five times larger.
Much of the biology involving Hbp remains to be elucidated. No
surface protein from either E. coli or B. fragilis has yet been
identified that can interact with Hbp and receive heme from it,
yet these must presumably exist given the known effects of the
protein on these bacteria under conditions of iron limitation.
B. fragilis up-regulates expression of a number of proteins under
iron-limiting conditions (47), and these are currently being ex-
amined as possible receptors for Hbp.
One functional role of Hbp is to remove heme from Hb and
supply it to bacteria growing within the body. The crystal
structure shows a novel trypsin-like serine protease domain
that is well conserved among the SPATE family. The overall
-helix architecture is also common to the ATs, but different
loops and domains carried by this stable fold appear to give the
proteins distinctive functional properties. Hbp does not have a
sequence motif or structural domain, which resembles a known
heme binding site. Further heme binding studies with mutants
of Hbp and other ATs are currently underway to determine how
heme interacts with Hbp.
Homology models of other ATs based on the Hbp structure
described here will hopefully be useful in designing new exper-
iments to test their functional roles and find ways to block their
activity. Hbp may be a convenient vehicle for presenting pep-
tides for antibody and vaccine production, by inserting them in
place of domain 2. Domain 2 itself may well allow us to produce
a clinically useful vaccine to reduce substantially the occur-
rence of severe peritonitis.
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